Here are three things to know from the study:
- TESI could provide a therapeutic alternative to the current standard treatment of SBS, solving challenges such as donor shortages in regard to transplants of the intestine as well as immunosupression.
- Researchers previously demonstrated TESI replicates key components of native intestine.
- The new study shows TESI holds a “well-differentiated epithelium with intact ion transporters/channels, functional brush-border enzymes and similar ultrastructural components to native tissue, including progenitor cells, whether derived from mouse or human cells.”
You can view the study abstract here.
More articles on GI/endoscopy:
Gastroenterology special issue: “You are what you eat”
Boston Scientific sales hit $1.77 billion in Q1: 5 things to know
GI physician leader to know: Dr. Lawrence Kosinski of Illinois Gastroenterology Group
